Evaluation of cefoxitin prophylaxis for cesarean section.
Prophylactic cefoxitin was evaluated in 101 patients undergoing cesarean section. A three-dose regimen of either cefoxitin or placebo was administered randomly in a double-blind manner, 46 patients receiving cefoxitin and 55 placebo, with the first dose given after the cord was clamped. In the placebo group, 29% of the patients developed pelvic or wound infection, compared to 4% in the cefoxitin group (P less than 0.003). No patient required re-operation, re-admission, or had a life threatening infection. Ten risk factors for infection were analyzed to help ascertain which patients would benefit from prophylaxis. Cefoxitin, with a broad spectrum of aerobic and anaerobic coverage, was found to be an effective and safe prophylactic agent when given to all patients undergoing cesarean section.
D000328:Adult; D002440:Cefoxitin / Q000627:therapeutic use*; D002585:Cesarean Section; D004311:Double-Blind Method; D004716:Endometritis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D011897:Random Allocation; D013530:Surgical Wound Infection / Q000517:prevention & control
D002440:Cefoxitin